Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
Looking Into Danaher's Recent Short Interest
Capricor Stock Rallies 20% on DMD Data Presentation Update
RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Lowers Price Target to $425
Vertex Pharmaceuticals Analyst Ratings
Regeneron Pharmaceuticals Analyst Ratings
Evaluating Eli Lilly Against Peers In Pharmaceuticals Industry
England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access
Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses
Thermo Fisher Plant Making Astra/ Sanofi RSV Drug Reportedly Breached FDA Rules
Futu Morning Post | Fund managers are entering the Chinese stock market at a record speed! The 'China Dragon' ETF lands in the US stock market; foreign capital accelerates its positions! Morgan Stanley increases its shareholding in BYD and other companies
The size of the USA money market fund has reached a record $6.46 trillion; Biden's vague stance has sparked an energy storm, causing international oil prices to soar by over 5%; just after raising funds, OpenAI secured a $4 billion credit line, with liquid assets exceeding over $10 billion.
US regulators said eli lilly and co's weight loss miracle drug is no longer in short supply, causing "平替" manufacturer Hims & Hers to drop nearly 10%.
FDA stated that eli lilly and co's two exenatide-containing GLP-1 injection Zepbound and Mounjaro have been in short supply since 2022 due to increased demand, but the shortage issue is now resolved. Industry organizations say that FDA's determination equals to pharmacies stopping the allocation and distribution of generic versions of the two drugs.
Wells Fargo's 'Core' Stocks: GOOGL, HD, KO, and More
Market Whales and Their Recent Bets on REGN Options
Cracking The Code: Understanding Analyst Reviews For Eli Lilly
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
Deutsche Bank Reiterates Buy on Eli Lilly, Maintains $1025 Price Target
Eli Lilly Analyst Ratings
Avidity Gets FDA Partial Clinical Hold Lifted on DM1 Drug Candidate
Popular Weight Loss Drugs Like Ozempic Show Gap Between Clinical Trial Promises And Real-World Use, Study Reveals